Targeting Bcl-2 for cancer therapy

被引：90
作者：
Zhang, Linlin [1 ]
Lu, Zaiming [1 ]
Zhao, Xiangxuan [1 ]
机构：
[1] China Med Univ, Dept Radiol, Shengjing Hosp, 36 Sanhao St, Shenyang 110004, Liaoning, Peoples R China
来源：
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER | 2021年 / 1876卷 / 01期
基金：
中国国家自然科学基金;
关键词：
Bcl-2; Apoptosis; Cancer; Target therapy; Drug resistance; CELL LUNG-CANCER; PAN-BCL-2 FAMILY ANTAGONIST; ACUTE MYELOID-LEUKEMIA; CHRONIC LYMPHOCYTIC-LEUKEMIA; OBATOCLAX MESYLATE GX15-070; CISPLATIN-INDUCED APOPTOSIS; ADVANCED BREAST-CANCER; BH3 MIMETIC ABT-199; PHASE-I TRIAL; PROMOTES APOPTOSIS;
D O I：
10.1016/j.bbcan.2021.188569
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Apoptosis deficiency is one of the most important features observed in neoplastic diseases. The Bcl-2 family is composed of a subset of proteins that act as decisive apoptosis regulators. Research and clinical studies have both demonstrated that the hyperactivation of Bcl-2-related anti-apoptotic effects correlates with cancer occurrence, progression and prognosis, also having a role in facilitating the radio- and chemoresistance of various malignancies. Therefore, targeting Bcl-2 inactivation has provided some compelling therapeutic advantages by enhancing apoptotic sensitivity or reversing drug resistance. Therefore, this pharmacological route turned into one of the most promising routes for cancer treatment. This review discusses some of the well-defined and emerging roles of Bcl-2 as well as its potential clinical value in cancer therapeutics.
引用
收藏
页数：17
相关论文
共 251 条
[41]   NOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263 [J].
Dastur, Anahita ;
Choi, Ahyun ;
Costa, Carlotta ;
Yin, Xunqin ;
Williams, August ;
McClanaghan, Joseph ;
Greenberg, Max ;
Roderick, Justine ;
Patel, Neha U. ;
Boisvert, Jessica ;
McDermott, Ultan ;
Garnett, Mathew J. ;
Almenara, Jorge ;
Grant, Steven ;
Rizzo, Kathryn ;
Engelman, Jeffrey A. ;
Kelliher, Michelle ;
Faber, Anthony C. ;
Benes, Cyril H. .
CLINICAL CANCER RESEARCH, 2019, 25 (01) :312-324
[42]   Targeting BCL-2 in B-cell lymphomas [J].
Davids, Matthew S. .
BLOOD, 2017, 130 (09) :1081-1088
[43]   ABT-199: Taking Dead Aim at BCL-2 [J].
Davids, Matthew S. ;
Letai, Anthony .
CANCER CELL, 2013, 23 (02) :139-141
[44]   Targeting the B-Cell Lymphoma/Leukemia 2 Family in Cancer [J].
Davids, Matthew S. ;
Letai, Anthony .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (25) :3127-3135
[45]   Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma [J].
de Jong, Mathilde Rikje Willemijn ;
Langendonk, Myra ;
Reitsma, Bart ;
Nijland, Marcel ;
van den Berg, Anke ;
Ammatuna, Emanuele ;
Visser, Lydia ;
van Meerten, Tom .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (23)
[46]   Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase 1b dose-finding study [J].
de Vos, S. ;
Swinnen, L. J. ;
Wang, D. ;
Reid, E. ;
Fowler, N. ;
Cordero, J. ;
Dunbar, M. ;
Enschede, S. H. ;
Nolan, C. ;
Petrich, A. M. ;
Ross, J. A. ;
Salem, A. H. ;
Verdugo, M. ;
Agarwal, S. ;
Zhou, L. ;
Kozloff, M. ;
Nastoupil, L. J. ;
Flowers, C. R. .
ANNALS OF ONCOLOGY, 2018, 29 (09) :1932-1938
[47]   Pristimerin, a quinonemethide triterpenoid, induces apoptosis in pancreatic cancer cells through the inhibition of pro-survival Akt/NF-κB/mTOR signaling proteins and anti-apoptotic Bcl-2 [J].
Deeb, Dorrah ;
Gao, Xiaohua ;
Liu, Yong Bo ;
Pindolia, Kirit ;
Gautam, Subhash C. .
INTERNATIONAL JOURNAL OF ONCOLOGY, 2014, 44 (05) :1707-1715
[48]   Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies [J].
Delbridge, Alex R. D. ;
Grabow, Stephanie ;
Strasser, Andreas ;
Vaux, David L. .
NATURE REVIEWS CANCER, 2016, 16 (02) :99-109
[49]   Exosome-transmitted LINC00461 promotes multiple myeloma cell proliferation and suppresses apoptosis by modulating microRNA/BCL-2 expression [J].
Deng, Mingyang ;
Yuan, Huan ;
Liu, Sufang ;
Hu, Zhiping ;
Xiao, Han .
CYTOTHERAPY, 2019, 21 (01) :96-106
[50]   Phase II trial of curcumin in patients with advanced pancreatic cancer [J].
Dhillon, Navneet ;
Aggarwal, Bharat B. ;
Newman, Robert A. ;
Wolff, Robert A. ;
Kunnumakkara, Ajaikumar B. ;
Abbruzzese, James L. ;
Ng, Chaan S. ;
Badmaev, Vladimir ;
Kurzrock, Razelle .
CLINICAL CANCER RESEARCH, 2008, 14 (14) :4491-4499
12345678910